Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of the Immunogenicity and Safety of Marketed Vaccines for COVID-19 After Regular Schedule and Adapted Vaccine Schedules and Routes: BNT162b2, mRNA-1273 Vaccine and ChAdOx1-S [Recombinant]

NCT06189040 is registered in ClinicalTrials.gov with Universiteit Antwerpen as lead sponsor.

NCT NCT06189040
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06189040 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of the Immunogenicity and Safety of Marketed Vaccines for COVID-19 After Regular Schedule and Adapted Vaccine Schedules and Routes: BNT162b2, mRNA-1273 Vaccine and ChAdOx1-S [Recombinant]
Lead sponsor
Universiteit Antwerpen
Phase
Phase 4
Overall status
Completed
Start date
May 26, 2021
Completion date
July 8, 2022
Enrollment
580 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus disease 2019, covid-19